Evidence map›Paper›PMID 29849781›Full record

ArticleExperimental and therapeutic medicine2018

miR-423-5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer.

Xuebiao Tang, Xiaogang Zeng, Yu Huang, Shibing Chen, Fang Lin, Ge Yang, Nian Yang

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Non-coding RNA · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. International journal of molecular sciences · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. TheAnnals of translational medicine · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer.Journal of experimental & clinical cancer research : CR · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuebiao TangDepartment of Medical Laboratory, The Second People's Hospital of Neijiang City, Neijiang, Sichuan 641100, P.R. China.
Xiaogang ZengDepartment of Medical Laboratory, The Traditional Chinese Medicine Hospital of Neijiang City, Neijiang, Sichuan 641000, P.R. China.
Yu HuangDepartment of Gynecology and Obstetrics, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Shibing ChenDepartment of Gynecology, The First People's Hospital of Neijiang City, Neijiang, Sichuan 641000, P.R. China.
Fang LinDepartment of Oncology, The Second People's Hospital of Neijiang City, Neijiang, Sichuan 641100, P.R. China.
Ge YangDepartment of Transformational Medicine, The Second People's Hospital of Neijiang City, Neijiang, Sichuan 641100, P.R. China.
Nian YangDepartment of Gynecology and Obstetrics, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miR)-423-5p is a potential target for the diagnosis and therapy of heart failure and cancer. The present study aimed to investigate the expression and role of miR-423-5p in ovarian cancer. miR-423-5p expression in ovarian tissues and plasma collected from ovarian cancer patients and healthy volunteers was analyzed by polymerase chain reaction analysis. In addition, a cell proliferation assay, clonogenic assay and Matrigel-based assay were performed to evaluate the role of miR-423-5p in ovarian cancer cells. The results demonstrated that miR-423-5p was downregulated in ovarian cancer tissues and plasma from ovarian cancer patients, compared with healthy individuals. Of note, miR-423-5p expression in ovarian tissues and plasma was demonstrated to be inversely correlated with ovarian cancer progression. Transfection with miR-423-5p efficiently increased miR-423-5p expression in A2780-s and A2780-cp cells, which had low miR-423-5p expression. Ectopic overexpression of miR-423-5p reduced cell proliferation, colony formation and invasion of ovarian cancer cells. In conclusion, the present study indicated that miR-423-5p may serve as a diagnostic indicator and functions as a tumor suppressor in ovarian cancer.

Indexed as

diagnosismiR-423-5povarian cancerprogression

Identifiers

PMID29849781
PMCPMC5960745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.